UroGen Pharma Announces March 2021 Conference Schedule

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq:URGN) has announced its participation in two virtual conferences in March 2021. The Cowen 41^st Annual Health Care Conference will take place on March 2 at 9:10 AM Eastern Time, followed by the Oppenheimer 31^st Annual Healthcare Conference on March 16 at 1:10 PM Eastern Time. Each event will be webcast live, with replays available on the company’s website for approximately 30 days. UroGen specializes in developing innovative solutions for treating specialty cancers and urologic diseases, including its investigational treatment UGN-102.

Positive

• UroGen is actively participating in prominent healthcare conferences, enhancing visibility.
• The company showcases commitment to advancing treatment options with its proprietary RTGel™ technology.

Negative

• None.

UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in March 2021:

• Cowen 41^st Annual Health Care Conference
  • Tuesday, March 2
  • 9:10AM Eastern Time
• Oppenheimer 31^st Annual Healthcare Conference
  • Tuesday, March 16
  • 1:10PM Eastern Time

A live webcast of each event will be available on the Investors & Media section of UroGen's website at www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005336/en/

FAQ

What conferences is UroGen Pharma attending in March 2021?

UroGen Pharma is attending the Cowen 41^st Annual Health Care Conference on March 2 and the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021.

What time will UroGen Pharma present at the Cowen Conference?

UroGen Pharma will present at the Cowen 41^st Annual Health Care Conference on March 2, 2021, at 9:10 AM Eastern Time.

Where can I watch UroGen Pharma's conference presentations?

UroGen Pharma's conference presentations can be accessed via live webcasts on their Investors & Media section of their website, with replays available for about 30 days.

What is UroGen Pharma’s main focus?

UroGen Pharma focuses on developing novel solutions for treating specialty cancers and urologic diseases.

What is UGN-102?

UGN-102 is UroGen's investigational treatment designed for patients with low-grade non-muscle invasive bladder cancer.